We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 269

FTC continues aggressive posture on reverse payment settlement agreements with reference to disgorgement

  • Cadwalader Wickersham & Taft LLP
  • -
  • USA
  • -
  • April 3 2014

In two recent statements, the FTC reaffirmed its intention aggressively to pursue reverse-payment patent settlement agreements in the pharmaceutical

US Supreme Court sets forth standing requirement for Lanham Act Section 43(a) false advertising claims, rejecting requirement of direct competition

  • Kaye Scholer LLP
  • -
  • USA
  • -
  • March 26 2014

Significant for litigators and would-be litigants alike, the US Supreme Court's unanimous decision in Lexmark Int'l, Inc. v. Static Control

Business law update - Spring 2014

  • Thompson Hine LLP
  • -
  • Canada, China, Germany, Japan, USA
  • -
  • March 24 2014

With deals today being larger and more global than ever before, a merger between two U.S. companies may have far-reaching effects in countries around

SanDisk sues PAE Round Rock for antitrust violations, breach of contract involving enforcement of former Micron patents

  • Kelley Drye & Warren LLP
  • -
  • USA
  • -
  • March 24 2014

SanDisk brought suit against Round Rock Research in the District of Delaware last week, alleging that the patent assertion entity's acquisition and

Antitrust: scrutiny of reverse payment settlements

  • Haynes and Boone LLP
  • -
  • USA
  • -
  • March 19 2014

It has been less than a year since the Supreme Court handed down its decision in FTC v. Actavis, Inc., 133 S. Ct. 2223 (2013) (hereinafter “Actavis”

FTC targets reporting of licensing of pharmaceutical patents with special rules for Premerger Notification: what you need to know

  • Sheppard Mullin Richter & Hampton LLP
  • -
  • USA
  • -
  • March 19 2014

On November 15, 2013, the Federal Trade Commission ("FTC") adopted special rules for determining whether "exclusive" licenses of pharmaceutical

Highlights of the DOJ Deputy Assistant Attorney General Antitrust Division’s keynote address applying the joint DOJPTO Policy Statement at the ITC

  • King & Spalding LLP
  • -
  • USA
  • -
  • March 13 2014

On February 26, 2014, Renata B. Hesse, Deputy Assistant Attorney General Antitrust Division of the U.S. Department of Justice (DOJ), gave a keynote

Pharmaceutical association calls out FTC in filing seeking to enjoin new rule targeting the industry

  • Baker & Hostetler LLP
  • -
  • USA
  • -
  • February 20 2014

Last November, the Federal Trade Commission (FTC) with the "concurrence" of the Antitrust Division of the Justice Department and over the strenuous

Cash-payment rule needed for pay-for-delay litigation frenzy

  • Fish & Richardson PC
  • -
  • USA
  • -
  • February 13 2014

The fallout from the Supreme Court's decision last Summer in FTC v. Actavis remains unabated as a host of purported classes of direct and indirect

Federal judge limits antitrust scrutiny of pharmaceutical reverse payments to settlements involving monetary transfers

  • Hogan Lovells
  • -
  • USA
  • -
  • February 7 2014

Recently, a federal judge in the U.S. District Court for the District of New Jersey held that only patent settlements involving a reverse monetary